PortViewPortView
Conexeu Sciences logo

Conexeu Sciences (CNXU) Stock Analysis

NASDAQHealthcareBiotechnology

$5.65-3.75%
1-year price historyRange $5.62 – $16.85
52-week range$5.65
$5.38$18.79

What Conexeu Sciences does

Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada.

Key metrics

Market cap
$151.18M
P/E (TTM)
-28.25
EPS (TTM)
$-0.20
Beta
0.51
50-day avg
$9.01
200-day avg
$10.34
52-week high
$18.79
52-week low
$5.38
CEO
Miles Harrison

ETFs linked to CNXU

Broad-market and Healthcare sector ETFs an investor holding Conexeu Sciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CNXU fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze CNXU in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Conexeu Sciences?
Conexeu Sciences trades under the ticker CNXU on NASDAQ.
Which exchange is CNXU listed on?
CNXU is listed on NASDAQ.
What sector does Conexeu Sciences operate in?
Conexeu Sciences is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze CNXU in a portfolio?
PortView shows CNXU's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.